Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdVMART1-transduced dendritic cells
- Development stage
- Unknown
- Lead developer
- University of California, Los Angeles
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
AdVMART1-transduced dendritic cells is an autologous cell-based cancer vaccine consisting of dendritic cells (DCs) genetically modified with a replication-defective, E1-deleted adenoviral vector (AdV) encoding the full-length melanoma antigen MART-1 (also known as Melan-A). The vaccine is designed to treat metastatic melanoma by utilizing the dendritic cells to present MART-1 epitopes to the immune system, thereby stimulating a robust antigen-specific response involving CD8+ cytotoxic T lymphocytes, CD4+ helper T cells, and natural killer (NK) cells. Developed primarily through research at UCLA and manufactured for clinical trials by Molecular Medicine, LLC, this therapy has demonstrated safety and immunogenicity in Phase 1/2 clinical settings.
- Other names
- AdVMART1 + dendritic cellsMART-1-engineered dendritic cellsMART1-engineered dendritic cellsMART 1-engineered dendritic cellsMART-1 melanoma antigen-engineered DCMART1 melanoma antigen-engineered DCMART 1 melanoma antigen-engineered DCAdVMART1-transduced DC vaccineAdVMART-1-transduced DC vaccineAdVMART 1-transduced DC vaccine
Beyond the preview
Go deeper on AdVMART1-transduced dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdVMART1-transduced dendritic cells.